198 related articles for article (PubMed ID: 36787291)
1. Pharmacological vitamin C inhibits mTOR signaling and tumor growth by degrading Rictor and inducing HMOX1 expression.
Qin S; Wang G; Chen L; Geng H; Zheng Y; Xia C; Wu S; Yao J; Deng L
PLoS Genet; 2023 Feb; 19(2):e1010629. PubMed ID: 36787291
[TBL] [Abstract][Full Text] [Related]
2. Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.
Koo J; Wu X; Mao Z; Khuri FR; Sun SY
J Biol Chem; 2015 May; 290(22):14120-9. PubMed ID: 25897075
[TBL] [Abstract][Full Text] [Related]
3. mTORC2 Suppresses GSK3-Dependent Snail Degradation to Positively Regulate Cancer Cell Invasion and Metastasis.
Zhang S; Qian G; Zhang QQ; Yao Y; Wang D; Chen ZG; Wang LJ; Chen M; Sun SY
Cancer Res; 2019 Jul; 79(14):3725-3736. PubMed ID: 31142514
[TBL] [Abstract][Full Text] [Related]
4. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
5. mTOR hyperactivity and
Sztankovics D; Moldvai D; Petővári G; Dankó T; Szalai F; Miyaura R; Varga V; Nagy N; Papp G; Pápay J; Krencz I; Sebestyén A
Pathol Oncol Res; 2024; 30():1611643. PubMed ID: 38515456
[TBL] [Abstract][Full Text] [Related]
6. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
[TBL] [Abstract][Full Text] [Related]
7. MITF-MIR211 axis is a novel autophagy amplifier system during cellular stress.
Ozturk DG; Kocak M; Akcay A; Kinoglu K; Kara E; Buyuk Y; Kazan H; Gozuacik D
Autophagy; 2019 Mar; 15(3):375-390. PubMed ID: 30290719
[TBL] [Abstract][Full Text] [Related]
8. The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling.
Yoon MS
Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077002
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
10. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.
Li S; Oh YT; Yue P; Khuri FR; Sun SY
Oncogene; 2016 Feb; 35(5):642-50. PubMed ID: 25893295
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
13. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
14. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
[TBL] [Abstract][Full Text] [Related]
15. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
Misra UK; Pizzo SV
PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin and mTORC2 inhibition synergistically reduce contraction-stimulated muscle protein synthesis.
Ogasawara R; Knudsen JR; Li J; Ato S; Jensen TE
J Physiol; 2020 Dec; 598(23):5453-5466. PubMed ID: 32893874
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
[TBL] [Abstract][Full Text] [Related]
18. mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.
Koo J; Yue P; Deng X; Khuri FR; Sun SY
Mol Cell Biol; 2015 Jul; 35(13):2344-55. PubMed ID: 25918246
[TBL] [Abstract][Full Text] [Related]
19. Identification of rictor as a novel substrate of Polo-like kinase 1.
Shao T; Liu X
Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
[TBL] [Abstract][Full Text] [Related]
20. The role of RICTOR downstream of receptor tyrosine kinase in cancers.
Jebali A; Dumaz N
Mol Cancer; 2018 Feb; 17(1):39. PubMed ID: 29455662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
